X-Ray Crystallography of Carbonic Anhydrase Inhibitors and Its Importance in Drug Design

Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications

Volumn , Issue , 2009, Pages 73-138

  Alterio, Vincenzo ^a   Di Fiore, Anna ^a   D'Ambrosio, Katia ^a   Supuran, Claudi T ^b   De Simone, Giuseppina ^a  

^a CNR   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Three dimensional structures of hCA II inhibitor complexes; X ray crystallography of CAIs and importance in drug design; Zinc binding group (ZBG), organic scaffold and "tails" in potent CAI

Indexed keywords

EID: 84889476926     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470508169.ch4     Document Type: Chapter

References (172)

1. Maren, T. H. Carbonic anhydrase: chemistry, physiology and inhibition. Physiol. Rev. 1967, 47, 595-781.
2. Supuran, C. T.; Scozzafava, A.; Conway, J. Carbonic Anhydrase: Its Inhibitors and Activators, CRC Press: Boca Raton, 2004; pp 1-363.
3. Supuran, C. T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 2008, 7, 168-181.
4. Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 2003, 23, 146-189.
5. Supuran, C. T. Carbonic anhydrases as drug targets: an overview. Curr. Top. Med. Chem. 2007, 7, 825-833.
6. Lehtonen, J. M.; Shen, B.; Vihinen, M.; Casini, A.; Scozzafava, A.; Supuran, C. T.; Parkkila, A.-K.; Saarnio, J.; Kivelä, A. J.; Waheed, A.; Sly, W. S.; Parkkila, S. Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J. Biol. Chem. 2004, 279, 2719-2727.
7. Köhler, K.; Hillebrecht, A.; SchulzeWischeler, J.; Innocenti, A.; Heine, A.; Supuran, C. T.; Klebe, G. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew. Chem. Int. Ed. Engl. 2007, 46, 7697-7699.
8. Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 2004, 19, 199-229.
9. Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin. Ther. Pat. 2004, 14, 667-702.
10. Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert. Opin. Ther. Pat. 2006, 16, 1627-1664.
11. Supuran, C. T.; Scozzafava, A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg. Med. Chem. 2007, 15, 4336-4350.
12. Winum, J.-Y.; Scozzafava, A.; Montero, J.-L.; Supuran, C.T. Newzinc bindingmotifs inthe design of selective carbonic anhydrase inhibitors. Bioorg. Med. Chem. 2006, 6, 921-936.
13. Hilvo, M.; Rafajová, M.; Pastoreková, S.; Pastorek, J.; Parkkila, S. Expression of carbonic anhydrase IX in mouse tissues. J.Histochem.Cytochem. 2004, 52, 1313-1322.
14. Kaunisto, K.; Parkkila, S.; Rajaniemi, H.; Waheed, A.; Grubb, J.; Sly, W. S. Carbonic anhydrase XIV: luminal expression suggests key role in renal acidification. Kidney Int. 2002, 61, 2111-2118.
15. Kyllönen, M. S.; Parkkila, S.; Rajaniemi, H.; Waheed, A.; Grubb, J. H.; Shah, G. N.; Sly, W. S.; Kaunisto, K. Localization of carbonic anhydrase XII to the basolateral membrane of H{thorn}-secreting cells of mouse and rat kidney. J. Histochem. Cytochem. 2003, 51, 1217-1224.
16. Menchise, V.; De Simone, G.; Alterio, V.; Di Fiore, A.; Pedone, C.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J. Med. Chem. 2005, 48, 5721-5727.
17. Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: newpharmacological opportunities due to related binding site recognition. J. Med. Chem. 2004, 47, 550-557.
18. Abbate, F.; Casini, A.; Owa, T.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 217-223.
19. Alterio, V.; Vitale, R. M.; Monti, S. M.; Pedone, C.; Scozzafava, A.; Cecchi, A.; De Simone, G.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J. Am. Chem. Soc. 2006, 128, 8329-8335.
20. Alterio, V.; De Simone, G.; Monti, S. M.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides-solution and crystallographic studies. Bioorg. Med. Chem. Lett. 2007, 17, 4201-4207.
21. De Simone, G.; Di Fiore, A.; Menchise, V.; Pedone, C.; Antel, J.; Casini, A.; Scozzafava, A.; Wurl, M.; Supuran, C. T. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 2005, 15, 2315-2320.
22. Boriack, P. A.; Christianson, D. W.; Kingery-Wood, J.; Whitesides, G. M. Secondary interactions significantly removed from the sulfonamide binding pocket of carbonic anhydrase II influence inhibitor binding constants. J. Med. Chem. 1995, 38, 2286-2291.
23. Casini, A.; Antel, J.; Abbate, F.; Scozzafava, A.; David, S.; Waldeck, H.; Schafer, S.; Supuran, C. T. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg. Med. Chem. Lett. 2003, 13, 841-845.
24. Kim, C.-Y.; Chang, J. S.; Doyon, J. B.; Baird, T. T.; Fierke, C. A.; Jain, A.; Christianson, D. W. Contribution of fluorine to protein-ligand affinity in the binding of fluoroaromatic inhibitors to carbonic anhydrase II. J. Am. Chem. Soc. 2000, 122, 12125-12134.
25. Smith, G. M.; Alexander, R. S.; Christianson, D.W.; McKeever, B. M.; Ponticello, G. S.; Springer, J. P.; Randall, W. C.; Baldwin, J. J.; Habecker, C. N. Positions of His-64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors. Protein Sci. 1994, 3, 118-125.
26. Stams, T.; Chen, Y.; Boriack-Sjodin, P. A.; Hurt, J. D.; Liao, J.; May, J. A.; Dean, T.; Laipis, P.; Silverman, D. N.; Christianson, D.W. Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Protein Sci. 1998, 7, 556-563.
27. Whittington, D. A.; Waheed, A.; Ulmasov, B.; Shah, G. N.; Grubb, J. H.; Sly, W. S.; Christianson, D. W. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc. Natl. Acad. Sci. USA 2001, 98, 9545-9550.
28. Boriack-Sjodin, P. A.; Heck, R. W.; Laipis, P. J.; Silverman, D. N.; Christianson, D. W. Structure determination of murine mitochondrial carbonic anhydrase V at 2.45 Å resolution: implications for catalytic proton transfer and inhibitor design. Proc. Natl. Acad. Sci. USA 1995, 92, 10949-10953.
29. Kannan, K. K.; Ramanadham, M.; Jones, T. A. Structure, refinement, and function of carbonic anhydrase isozymes: refinement of human carbonic anhydrase I. Ann. N.Y. Acad. Sci. 1984, 429, 49-60.
30. Eriksson, A. E.; Jones, T. A.; Liljas, A. Refined structure of human carbonic anhydrase II at 2.0 Å resolution. Proteins 1988, 4, 274-282.
31. Eriksson, A. E.; Liljas, A. Refined structure of bovine carbonic anhydrase III at 2.0 Å resolution. Proteins 1993, 16, 29-42.
32. Duda, D. M.; Tu, C.; Fisher, S. Z.; An, H.; Yoshioka, C.; Govindasamy, L.; Laipis, P. J.; Agbandje-McKenna, M.; Silverman, D. N.; McKenna, R. Human carbonic anhydrase III: structural and kinetic study of catalysis and proton transfer. Biochemistry 2005, 44, 10046-10053.
33. Stams, T.; Nair, S. K.; Okuyama, T.; Waheed, A.; Sly, W. S.; Christianson, D.W. Crystal structure of the secretory form of membrane-associated human carbonic anhydrase IVat 2.8 Å resolution. Proc. Natl. Acad. Sci. USA 1996, 93, 13589-13594.
34. Whittington, D. A.; Grubb, J. H.; Waheed, A.; Shah, G. N.; Sly, W. S.; Christianson, D.W. Expression, assay, and structure of the extracellular domain of murine carbonic anhydrase XIV: implications for selective inhibition of membrane-associated isozymes. J. Biol. Chem. 2004, 279, 7223-7228.
35. Di Fiore, A.; Monti, S. M.; Hilvo, M.; Parkkila, S.; Romano, V.; Scaloni, A.; Pedone, C.; Scozzafava, A.; Supuran, C. T.; De Simone, G. Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins 2008, 74, 164-175.
36. Håkansson, K.; Carlsson, M.; Svensson, L. A.; Liljas, A. Structure of native and apo carbonic anhydrase II and structure of some of its anion-ligand complexes. J. Mol. Biol. 1992, 227, 1192-1204.
37. Stams, T.; Christianson, D. W. X-ray crystallographic studies of mammalian carbonic anhydrase isozymes. In The Carbonic Anhydrases: New Horizons; Chegwidden,W. R.; Edwards, Y.; Carter, N.,Eds.; Birkhäuser Verlag: Basel, Switzerland, 2000; pp 159-174.
38. Christianson, D.W.; Fierke, C. A. Carbonic anhydrase: evolution of the zinc binding site by nature and by design. Acc. Chem. Res. 1996, 29, 331-339.
39. Lindskog, S. Structure and mechanism of carbonic anhydrase. Pharmacol. Ther. 1997, 74, 1-20.
40. Lindskog, S.; Silverman, D. W. The catalytic mechanism of mammalian carbonic anhydrases. In The Carbonic Anhydrases: New Horizons; Chegwidden, W. R.; Edwards, Y. H.; Carter, N. D.,Eds.; Birkhäuser Verlag: Basel, Switzerland, 2000; pp 175-195.
41. Winum, J.Y.;Temperini, C.; El Cheikh, K.; Innocenti, A.;Vullo, D.; Ciattini, S.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J. Med. Chem. 2006, 49, 7024-7031.
42. Güzel, O.; Temperini, C.; Innocenti, A.; Scozzafava, A.; Salman, A.; Supuran, C. T. Carbonic anhydrase inhibitors: interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 2008, 18, 152-158.
43. Di Fiore, A.; Pedone, C.; D'Ambrosio, K.; Scozzafava, A.; De Simone, G.; Supuran, C. T. Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II ''selective'' inhibitor celecoxib. Bioorg. Med. Chem. Lett. 2006, 16, 437-442.
44. Casini, A.; Abbate, F.; Scozzafava, A.; Supuran,C. T. Carbonic anhydrase inhibitors: Xray crystallographic structure of the adduct of human isozyme II with a bis-sulfonamidetwo heads are better than one? Bioorg. Med. Chem. Lett. 2003, 13, 2759-2763.
45. Liljas, A.; Håkansson, K.; Jonsson, B. H.; Xue, Y. Inhibition and catalysis of carbonic anhydrase. Recent crystallographic analyses. Eur. J. Biochem. 1994, 219, 1-10.
46. Thiry, A.; Dogné, J. M.; Supuran, C. T.; Masereel, B. Anticonvulsant sulfonamides/ sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action. Curr. Pharm. Des. 2008, 14, 661-671.
47. Briganti, F.; Mangani, S.; Scozzafava, A.; Vernaglione, G.; Supuran, C. T. Carbonic anhydrase catalyzes cyanamide hydration to urea: is it mimicking the physiological reaction? J. Biol. Inorg. Chem. 1999, 4, 528-536.
48. Guerri, A.; Briganti, F.; Scozzafava, A.; Supuran, C. T.; Mangani, S. Mechanism of cyanamide hydration catalyzed by carbonic anhydrase II suggested by cryogenic X-ray diffraction. Biochemistry 2000, 39, 12391-12397.
49. Scozzafava, A.; Supuran, C. T. Hydroxyurea is a carbonic anhydrase inhibitor. Bioorg. Med. Chem. 2003, 11, 2241-2246.
50. Temperini, C.; Innocenti, A.; Scozzafava, A.; Supuran, C. T. N-hydroxyurea: a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 4316-4320.
51. Scolnick, L. R.; Clements, A. M.; Liao, J.; Crenshaw, L.; Hellberg, M.; May, J.; Dean, T. R.; Christianson, D.W. Novel binding mode of hydroxamate inhibitors to human carbonic anhydrase II. J. Am. Chem. Soc. 1997, 119, 850-851.
52. Mangani, S.; Håkansson, K. Crystallographic studies of the binding of protonated and unprotonated inhibitors to carbonic anhydrase using hydrogen sulfide and nitrate anions. Eur. J. Biochem. 210; 1992, 867-871.
53. Jönsson, B. M.; Håkansson, K.; Liljas, A. The structure of human carbonic anhydrase II in complex with bromide and azide. FEBS Lett. 1992, 322, 186-190.
54. Nair, S. K.; Christianson, D. W. Crystallographic studies of azide binding to human carbonic anhydrase II. Eur. J. Biochem. 1993, 213, 507-515.
55. Eriksson, A. E.; Kylsten, P. M.; Jones, T. A.; Liljas, A. Crystallographic studies of inhibitor binding sites in human carbonic anhydrase II: a pentacoordinated binding of the SCN-ion to the zinc at high pH. Proteins 1983, 4, 283-293.
56. Lindahl, M.; Svensson, L. A.; Liljas, A. Metal poison inhibition of carbonic anhydrase. Proteins 1993, 15, 177-182.
57. Keilin, D.; Mann, T. Carbonic anhydrase. Purification and nature of the enzyme. Biochem. J. 1940, 34, 1163-1176.
58. Clare, B. W.; Supuran, C. T. A perspective on quantitative structure-activity relationships and carbonic anhydrase inhibitors. Expert Opin. Drug Metab. Toxicol. 2006, 2, 113-137.
59. Temperini, C.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase activation and the drug design. Curr. Pharm. Des. 2008, 14, 708-715.
60. De Simone, G.; Di Fiore, A.; Supuran, C. T. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr. Pharm. Des. 2008, 14, 655-660.
61. King, R. W; Burgen, A. S. Sulfonamide complexes of human carbonic anhydrases. Ultraviolet difference spectroscopy. Biochim. Biophys. Acta 1970, 207, 278-285.
62. Lindahl, M.; Vidgren, J.; Eriksson, E.; Habash, J.; Harrop, S.; Helliwell, J.; Liljas, A.; Lindeskog, M.;Walker, N.; Crystallographic studies of carbonic anhydrase inhibition. In Carbonic Anhydrase: From Biochemistry and Genetics to Physiology and Clinical Medicine; Botré, F.; Gros, G.; Storey, B. T.,Eds.; VCH: Weinheim, Germany, 1991; pp 111-118.
63. Abbate, F.; Supuran, C. T.; Scozzafava, A.; Orioli, P.; Stubbs, M. T.; Klebe, G. Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design. J. Med. Chem. 2002, 45, 3583-3587.
64. Beasley, Y. M.; Overell, B. G.; Petrow, V.; Stephenson, O. Some in vitro inhibitors of carbonic anhydrase. J. Pharm. Pharmacol. 1958, 10, 696-705.
65. Supuran, C. T. Carbonic anhydrase inhibitors. In Carbonic Anhydrase and Modulation of Physiological and Pathologic Processes in the Organism; Puscas, I.,Ed.; Helicon Press: Timisoara, Romania, 1994; pp 29-111.
66. Mincione, F.; Starnotti, M.; Menabuoni, L.; Scozzafava, A.; Casini, A.; Supuran, C. T. Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl- benzenecarboxamides with strong topical antiglaucoma properties. Bioorg. Med. Chem. Lett. 2001, 11, 1787-1791.
67. Jain, A.; Whitesides, G. M.; Alexander, R. S.; Christianson, D. W. Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solutionphase and solid-state studies and their use in the development of tight-binding inhibitors. J. Med. Chem. 1994, 37, 2100-2105.
68. Avila, L. Z.; Chu, Y. H.; Blossey, E. C.; Whitesides, G. M. Use of affinity capillary electrophoresis to determine kinetic and equilibrium constants for binding of arylsulfonamides to bovine carbonic anhydrase. J. Med. Chem. 1993, 36, 126-133.
69. Gao, J.; Qiao, S.; Whitesides, G. M. Increasing binding constants of ligands to carbonic anhydrase by using ''greasy tails''. J. Med. Chem. 1995, 38, 2292-2301.
70. Gao, J.; Cheng, X.; Chen, R.; Sigal, G. B.; Bruce, J. E.; Schwartz, B. L.; Hofstadler, S. A.; Anderson, G. A.; Smith, R. D.; Whiteside, G. M. Screening derivatized peptide libraries for tight binding inhibitors to carbonic anhydrase II by electrospray ionization-mass spectrometry. J. Med.Chem. 1996, 39, 1949-1955.
71. Jude, K. M.; Banerjee, A. L.; Haldar, M. K.; Manokaran, S.; Roy, B.; Mallik, S.; Srivastava, D. K.; Christianson, D. W. Ultrahigh resolution crystal structures of human carbonic anhydrases I and II complexed with two-prong inhibitors reveal the molecular basis of high affinity. J. Am. Chem. Soc. 2006, 128, 3011-3018.
72. Roy, B. C.; Banerjee, A. L.; Swanson, M.; Jia, X. G.; Haldar, M. K.; Mallik, S.; Srivastava, D. K. Two-prong inhibitors for human carbonic anhydrase II. J. Am. Chem. Soc. 2004, 126, 13206-13207.
73. Doyon, J. B.; Jain, A. The pattern of fluorine substitution affects binding affinity in a small library of fluoroaromatic inhibitors for carbonic anhydrase. Org. Lett. 1999, 1, 183-185.
74. Cappalonga Bunn, A. M.; Alexander, R. S.; Christianson, D.W. Mapping protein-peptide affinity: binding of peptidylsulfonamide inhibitors to human carbonic anhydrase II. J. Am. Chem. Soc. 1994, 116, 5063-5068.
75. Jain, A.; Huang, S. G.; Whitesides, G. M. Lack of effect of the length of oligoglycine- and oligo(ethy1ene glycol)-derived para-substituents on the amnity of benzenesulfonamides for carbonic anhydrase II in solution. J. Am. Chem. Soc. 1994, 116, 5057-5062.
76. Taylor, P.W.; King, R.W.; Burgen, A. S.V. Kinetics of complex formation between human carbonic anhydrases and aromatic sulfonamides. Biochemistry 1970, 9, 2638-2645.
77. Casini, A.; Scozzafava, A.; Mincione, F.; Menabuoni, L.; Ilies, M. A.; Supuran, C. T. Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects. J. Med. Chem. 2000, 43, 4884-4892.
78. Casini, A.; Scozzafava, A.; Mincione, F.; Menabuoni, L.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis of water soluble sulfonamides incorporating a 4-sulfamoylphenylmethylthiourea scaffold, with potent intraocular pressure lowering properties. J. Enzyme Inhib. Med. Chem. 2002, 17, 333-343.
79. Cecchi, A.; Winum, J.-Y.; Innocenti, A.; Vullo, D.; Montero, J.-L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. Bioorg. Med. Chem. Lett. 2004, 14, 5775-5780.
80. Innocenti, A.; Casini, A.; Alcaro, M. C.; Papini, A. M.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library. J. Med. Chem. 2004, 47, 5224-5229.
81. Di Fiore, A.; De Simone, G.; Menchise, V.; Pedone, C.; Casini, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray crystal structure of a benzenesulfonamide strong CA II and CA IX inhibitor bearing a pentafluorophenylaminothioureido tail in complex with isozyme II. Bioorg. Med. Chem. Lett. 2005, 15, 1937-1942.
82. Supuran, C. T.; Scozzafava, A.; Jurca, B. C.; Ilies, M. A. Carbonic anhydrase inhibitors. Part 49. Synthesis of substituted ureido and thioureido derivatives of aromatic/heterocyclic sulfonamides with increased affinities for isozyme I. Eur. J. Med. Chem. 1998, 33, 83-93.
83. Svastová, E.; Hulíková, A.; Rafajová, M.; Zat'ovicová, M.; Gibadulinová, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C. T.; Pastorek, J.; Pastoreková, S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577, 439-445.
84. Cecchi, A.; Hulikova, A.; Pastorek, J.; Pastoreková, S.; Scozzafava, A.; Winum, J. Y.; Montero, J. L.; Supuran, C. T. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J. Med. Chem. 2005, 48, 4834-4841.
85. Pastorekova, S.; Casini, A.; Scozzafava, A.; Vullo, D.; Pastorek, J.; Supuran, C. T. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 869-873.
86. Supuran, C. T.; Scozzafava, A.; Ilies, M. A.; Briganti, F. Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporatine 2,4,6-trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-impermeability and in vivo selectivity for the membrane-bound (CA IV) versus the cytosolic (CA I and CA II) isozymes. J. Enzyme Inhib. 2000, 15, 381-401.
87. Scozzafava, A.; Briganti, F.; Ilies, M. A.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. J. Med. Chem. 2000, 43, 292-300.
88. Supuran, C. T.; Scozzafava, A. Benzolamide is not a membrane-impermeant carbonic anhydrase inhibitor. J. Enzyme Inhib. Med. Chem. 2004, 19, 269-273.
89. Casey, J. R.; Morgan, P. E.; Vullo, D.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J. Med. Chem. 2004, 47, 2337-2347.
90. Balaban, A. T.; Dinculescu, A.; Dorofeenko, G. N.; Fischer, G. W.; Koblik, A. V.; Mezheritskii, V. V.; Schroth, W. Pyrylium salts: syntheses, reactions and physical properties. In Advances in Heterocyclic Chemistry; Katritzky, A. R., Ed.; Academic Press: New York, 1982; pp 8-360.
91. Supuran, C. T.; Manole, G.; Dinculescu, A.; Schiketanz, A.; Gheorghiu, M. D.; Puscas, I.; Balaban, A. T. Carbonic anhydrase inhibitors. V: Pyrylium salts in the synthesis of isozyme-specific inhibitors. J. Pharm. Sci. 1992, 81, 716-719.
92. Supuran, C. T.; Scozzafava, A.; Ilies, M. A.; Iorga, B.; Cristea, T.; Briganti, F.; Chiraleu, F.; Banciu, M. D. Carbonic anhydrase inhibitors. Part 53. Synthesis of substitutedpyridinium derivatives of aromatic sulfonamides: the first nonpolymeric membraneimpermeable inhibitors with selectivity for isozyme IV. Eur. J. Med. Chem. 1998, 33, 577-595.
93. Srivastava, D. K.; Jude, K. M.; Banerjee, A. L.; Haldar, M.; Manokaran, S.; Kooren, J.; Mallik, S.; Christianson, D.W. Structural analysis of charge discrimination in the binding of inhibitors to human carbonic anhydrases I and II. J. Am. Chem. Soc. 2007, 129, 5528-5537.
94. Supuran, C. T.; Scozzafava, A.; Casini, A. Development of sulfonamide carbonic anhydrase inhibitors. In Carbonic Anhydrase: Its inhibitors and Activators; Supuran, C. T.; Scozzafava, A.; Conway, J., Eds.; CRC Press: Boca Raton, FL, 2004; pp 67-147.
95. Mincione, F.; Menabuoni, L.; Supuran, C. T. Clinical applications of the carbonic anhydrase inhibitors in ophthalmology. In Carbonic Anhydrase, Its Inhibitors and Activators; Supuran, C. T.; Scozzafava, A.; Conway, J., Eds.; CRC Press: Boca Raton, FL, 2004; pp 243-254.
96. Tawil, R.; McDermott, M. P.; Brown, R., Jr.; Shapiro, B. C.; Ptacek, L. J.; McManis, P. G.; Dalakas, M. C.; Spector, S. A.; Mendell, J. R.; Hahn, A. F.; Griggs, R. C. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann. Neurol. 2000, 47, 46-53.
97. De Simone, G.; Supuran, C. T. Antiobesity carbonic anhydrase inhibitors. Curr. Top. Med. Chem. 2007, 7, 879-884.
98. Kim, C. Y.; Chandra, P. P.; Jain, A.; Christianson, D.W. Fluoroaromatic-fluoroaromatic interactions between inhibitors bound in the crystal lattice of human carbonic anhydrase II. J. Am. Chem. Soc. 2001, 123, 9620-9627.
99. May, J. A.; Namil, A.; Chen, H. H.; Dantanarayana, A. P.; Dupré, B.; Liao, J. C. Quaternary ammonium substituted thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides: potential membrane-impermeable inhibitors of carbonic anhydrase. Bioorg. Med. Chem. 2006, 14, 2052-2059.
100. Nishimori, I.; Vullo, D.; Innocenti, A.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J. Med. Chem. 2005, 48, 7860.
101. Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2003, 13, 1005-1009.
102. Winum, J.Y.; Dogné, J. M.; Casini, A.; de Leval, X.; Montero, J. L.; Scozzafava, A.;Vullo, D.; Innocenti, A.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. J. Med. Chem. 2005, 48, 2121-2125.
103. Abbate, F.; Coetzee, A.; Casini, A.; Ciattini, S.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorg. Med. Chem. Lett. 2004, 14, 337-341.
104. Chakravarty, S.; Kannan, K. K. Drug-protein interactions. Refined structures of three sulfonamide drug complexes of human carbonic anhydrase I enzyme. J. Mol. Biol. 1994, 243, 298-309.
105. Vidgren, J.; Liljas, A.;Walker, N. P. C. Refined structure of the acetazolamide complex of human carbonic anhydrase II at 1.9 Å . Int. J. Biol. Macromol. 1990, 12, 342-344.
106. Denny, W. A. Tumor-activated prodrugs. A new approach to cancer therapy. Cancer Invest. 2004, 22, 604-619.
107. De Simone, G.; Vitale, R. M.; Di Fiore, A.; Pedone, C.; Scozzafava, A.; Montero, J.-L.; Winum, J.-Y.; Supuran, C. T. Carbonic anhydrase inhibitors: hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J. Med. Chem. 2006, 49, 5544-5551.
108. D'Ambrosio, K.;Vitale, R. M.; Dogne, J. M.; Masereel, B.; Innocenti, A.; Scozzafava, A.; De Simone, G.; Supuran, C. T. Carbonic anhydrase inhibitors: bioreductive nitrocontaining sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII. J. Med. Chem. 2008, 51, 3230-3237.
109. Saczewski, F.; Sławinski, J.; Kornicka, A.; Brzozowski, Z.; Pomarnacka, E.; Innocenti, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. Bioorg. Med. Chem. Lett. 2006, 16, 4846-4851.
110. Hanson, J.; Dogné, J. M.; Ghiotto, J.; Moray, A. L.; Kinsella, B. T.; Pirotte, B. Design, synthesis, and SAR study of a series of N-alkyl-N0-[2-(aryloxy)-5-nitrobenzenesulfonyl] ureas and -cyanoguanidine as selective antagonists of the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor. J. Med. Chem. 2007, 50, 3928-3936.
111. FitzGerald, G. A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001, 345, 433-442.
112. Supuran, C. T.; Scozzafava, A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Pat. 2000, 10, 575-600.
113. Davemport, H.W. The inhibition of carbonic anhydrase by thiophene-2-sulfonamide and sulfanilamide. J. Biol. Chem. 1945, 158, 567-571.
114. Roblin, R. O., Jr.; Clapp, J. W. The preparation of heterocyclic sulfonamides. J. Am. Chem. Soc. 1950, 72, 4890-4892.
115. Miller, W. H.; Dessert, A. M.; Roblin, R. O., Jr. Heterocyclic sulfonamides as carbonic anhydrase inhibitors. J. Am. Chem. Soc. 1950, 72, 4893-4896.
116. Barnish, I. T.; Cross, P. E.; Dickinson, R. P.; Parry, M. J.; Randall, M. J. Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 3. 5-(Arylthio)-, 5-(arylsulfinyl)-, and 5-(arylsulfonyl)thiophene-2-sulfonamides. J. Med. Chem. 1981, 24, 959-964.
117. Maren, T. H. The development of topical carbonic anhydrase inhibitors. J. Glaucoma 1995, 4, 49-62.
118. Abbate, F.; Casini, A.; Scossafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Xray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors. J. Enzyme Inhib. Med. Chem. 2003, 18, 303-308.
119. Abbate, F.; Casini, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide. Bioorg. Med. Chem. Lett. 2004, 14, 2357-2361.
120. Boriack-Sjodin, P. A.; Zeitlin, S.; Chen, H. H.; Crenshaw, L.; Gross, S.; Dantanarayana, A.; Delgado, P.; May, J. A.; Dean, T.; Christianson, D.W. Structural analysis of inhibitor binding to human carbonic anhydrase II. Protein Sci. 1998, 7, 2483-2489.
121. Menchise, V.; De Simone, G.; Di Fiore, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of 5-amino-1,3,4- thiadiazole-2-sulfonamide and 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)-1,3,4- thiadiazole-2-sulfonamide to human isoform II. Bioorg. Med. Chem. Lett. 2006, 16, 6204-6208.
122. Vaughan, J. R.; Eichler, J. A.; Anderson, G. W. Heterocyclic sulfonamides as carbonic anhydrase inhibitors, 2-acylamino and 2-sulfonamido-1,3,4-thiadiazole-5-sulfonamides. J. Org. Chem. 1956, 21, 700-771.
123. Young, R. W.; Wood, K. H.; Vaughan, J. R.; Anderson, G. W. 1,3,4-Thiadiazole and thiadiazolinesulfonamides as carbonic anhydrase inhibitors. Synthesis and structural studies. J. Am. Chem. Soc. 1956, 78, 4649-4654.
124. Supuran, C. T.; Ilies, M. A.; Scozzafava, A. Carbonic anhydrase inhibitors. Part 29. Interaction of isozymes I, II and IV with benzolamide-like derivatives. Eur. J. Med. Chem. 1998, 33, 739-752.
125. Casini, A.; Scozzafava, A.; Mincione, F.; Menabuoni, L.; Starnotti, M.; Supurana, C. T. Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide. Bioorg. Med. Chem. Lett. 2003, 13, 2867-2873.
126. Scozzafava, A.; Menabuoni, L.; Mincione, F.; Briganti, F.; Mincione, G.; Supuran, C. T. Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/ heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J. Med. Chem. 2000, 43, 4542-4551.
127. Ilies, M. A.;Vullo, D.; Pastorek, J.; Scozzafava, A.; Ilies, M.; Caproiu, M. T.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J. Med. Chem. 2003, 46, 2187-2196.
128. Chow, K.; Lai, R.; Holmes, J. M.; Wijono, M.; Wheeler, L. A.; Garst, M. E. 5-Substituted 3-thiopenesulfonamides as carbonic anhydrase inhibitors. Eur. J. Med. Chem. 1996, 31, 175-186.
129. Supuran, C. T.; Scozzafava, A. Applications of carbonic anhydrase inhibitors and activators in therapy. Expert. Opin. Ther. Pat. 2002, 12, 217-242.
130. Kim, C. Y.; Whittington, D. A.; Chang, J. S.; Liao, J.; May, J. A.; Christianson, D. W. Structural aspects of isozyme selectivity in the binding of inhibitors to carbonic anhydrases II and IV. J. Med. Chem. 2002, 45, 888-893.
131. Nishimori, I.; Minakuchi, T.; Onishi, S.; Vullo, D.; Cecchi, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg. Med. Chem. 2007, 15, 7229-7236.
132. Di Fiore, A.; Pedone, C.; Antel, J.; Waldeck, H.; Witte, A.; Wurl, M.; Scozzafava, A.; Supuran, C.T.;De Simone, G. Carbonic anhydrase inhibitors: theX-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 2669-2674.
133. D'Ambrosio, K.; Masereel, B.; Thiry, A.; Scozzafava, A.; Supuran, C. T.; De Simone, G. Carbonic anhydrase inhibitors: binding of indanesulfonamides to the human isoform II. Chem. Med. Chem. 2008, 3, 473-477.
134. Gruneberg, S.; Stubbs, M. T.; Klebe, G. Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation. J. Med. Chem. 2002, 45, 3588-3602.
135. Chazalette, C.; Masereel, B.; Rolin, S.; Thiry, A.; Scozzafava, A.; Innocenti, A.; Supuran, C. T. Bioorg. Med. Chem. Lett. 2004, 14, 5781-5786.
136. Thiry, A.; Ledecq, M.; Cecchi, A.; Supuran, C.T.; Wouters, J.; Dogné, J.-M.; Masereel, B. J. Med. Chem. 2006, 49, 2743-2749.
137. Thiry, A.; Masereel, B.; Dogné, J.-M.; Supuran, C. T.; Wouters, J.; Michaux, C.; Chem. Med. Chem. 2007, 2, 1273-1280.
138. Maren, T. H.; Conroy, C.W. A new class of carbonic anhydrase inhibitor. J. Biol. Chem. 1993, 268, 26233-26239.
139. Håkansson, K.; Liljas, A. The structure of a complex between carbonic anhydrase II and a new inhibitor, trifluoromethane sulfonamide. FEBS Lett. 1994, 350, 319-322.
140. Temperini, C.; Cecchi, A.; Boyle, N. A.; Scozzafava, A.; Cabeza, J. E.; Wentworth, P.; Blackburn, G. M.; Supuran, C. T. Carbonic anhydrase inhibitors. Interaction of 2-N, N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 2008, 18, 999-1005.
141. Fisher, S. Z.; Govindasamy, L.; Boyle, N.; Agbandje-McKenna, M.; Silverman, D. N.; Blackburn, G. M.; McKenna, R. X-ray crystallographic studies reveal that the incorporation of spacer groups in carbonic anhydrase inhibitors causes alternate binding modes. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 2006, 62, 618-622.
142. Reed, M. J.; Purohit, A.; Newman, S. P.; Potter, B. V. L. Steroid sulfatase: molecular biology, regulation and inhibition. Endocr. Rev. 2005, 26, 171-202.
143. Stanway, S. J.; Purohit, A.; Woo, L. W. L.; Sufi, S.; Vigushin, D.; Ward, R.; Wilson, R.; Stanczyk, F. Z.; Dobbs, N.; Kulinkaya, E.; Elliott, M.; Potter, B. V. L.; Reed, M. J.; Coombs, R. C. Phase I study of STX64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 2006, 12, 1585-1592.
144. Ireson, C. R.; Chander, S. K.; Purohit, A.; Parish, D. A.; Woo, L. W. L.; Potter, B. V. L.; Reed, M. J. Pharmacokinetics of the non-steroidal steroid sulfatase inhibitor 667-coumate and its sequestration into red blood cells. Br. J. Cancer 2004, 91, 1399-1404.
145. Abbate, F.; Winum, J. Y.; Potter, B. V. L.; Casini, A.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg. Med. Chem. Lett. 2004, 14, 231-234.
146. Lloyd, M. D.; Pederick, R. L.; Natesh, R.; Woo, L. W. L.; Purohit, A.; Reed, M. J.; Acharya, K. R.; Potter, B.V. L. Crystal structure of human carbonic anhydrase II at 1.95Å resolution in complex with 667-coumate, a novel anti-cancer agent. Biochem. J. 2005, 385, 715-720.
147. Lloyd, M. D.; Thiyagarajan, N.; Ho, Y. T.; Woo, L. W. L.; Sutcliffe, O. B.; Purohit, A.; Reed, M. J.; Acharya, K. R.; Potter, B. V. L. First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors. Biochemistry 2005, 44, 6858-6866.
148. Leese, M. P.; Leblond, B.; Smith, A.; Newman, S. P.; Di Fiore, A.; De Simone, G.; Supuran, C. T.; Purohit, A.; Reed, M. J.; Potter, B. V. 2-Substituted estradiol bissulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J. Med. Chem. 2006, 49, 7683-7696.
149. Leese, M. P.; Jourdan, F. L.; Gaukroger, K.; Mahon, M. F.; Newman, S. P.; Foster, P. A.; Stengel, C.; Regis-Lydi, S.; Ferrandis, E.; Di Fiore, A.; De Simone, G.; Supuran, C. T.; Purohit, A.; Reed, M. J.; Potter, B. V. Structure-activity relationships of C-17 cyanosubstituted estratrienes as anticancer agents. J. Med. Chem. 2008, 51, 1295-1308.
150. Woo, L.W. L.; Fischer,D. S.; Sharland, C. M.; Trusselle, M.; Foster, P. A.; Chander, S. K.; Di Fiore, A.; Supuran, C. T.;De Simone, G.; Purohit, A.; Reed, M. J.; Potter, B.V. L. Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography. Mol. Cancer Ther. 2008, 7, 2435-2444.
151. Winum, J.-Y.; Vullo, D.; Casini, A.; Montero, J.-L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J. Med. Chem. 2003, 46, 2197-2204.
152. Elger, W.; Schwarz, S.; Hedden, A. M.; Reddersen, G.; Schneider, B. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol. 1995, 55, 395-403.
153. Fischer, D. S.; Woo, L. W.; Mahon, M. F.; Purohit, A.; Reed, M. J.; Potter, B. V. D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. Bioorg. Med. Chem. 2003, 11, 1685-1700.
154. Fischer, D. S.; Chander, S. K.;Woo, L.W.; Fenton, J. C.; Purohit, A.; Reed, M. J.; Potter, B. V. Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. J. Steroid. Biochem. Mol. Biol. 2003, 84, 343-349.
155. Woo, L.W. L.; Sutcliffe, O. B.; Bubert, C.; Grasso, A.; Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. L. First dual aromatase-steroid sulfatase inhibitors. J. Med. Chem. 2003, 46, 3193-3196.
156. Sugrue, M. F. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog. Retin. Eye Res. 2000, 19, 87-112.
157. Silver, L. H.; Brinzolamide Dose-Response Study Group. Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Surv. Ophthalmol. 2000, 44, (Suppl 2.), 147-153.
158. Colinas, P. A.; Bravo, R. D.;Vullo, D.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I and II, and extracellular isoforms IV, IX, and XII with sulfamides incorporating sugar moieties. Bioorg. Med. Chem. Lett. 2007, 17, 5086-5090.
159. Wilkinson, B. L.; Bornaghi, L. F.; Houston, T. A.; Innocenti, A.;Vullo, D.; Supuran, C. T.; Poulsen, S. A. Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg. Med. Chem. Lett. 2007, 17, 987-992.
160. Di Fiore, A.; Scozzafava, A.;Winum, J.Y.; Montero, J. L.; Pedone, C.; Supuran, C. T.; De Simone, G. Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties. Bioorg. Med. Chem. Lett. 2007, 17, 1726-1731.
161. Winum, J. Y.; Casini, A.; Minzione, F.; Starnotti, M.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg. Med. Chem. Lett. 2004, 14, 225-229.
162. Wilkinson, B. L.; Bornaghi, L. F.; Houston, T. A.; Innocenti, A.; Supuran, C. T.; Poulsen, S. A. A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by ''click-tailing''. J. Med. Chem. 2006, 49, 6539-6548.
163. Wilkinson, B. L.; Bornaghi, L. F.; Houston, T. A.; Innocenti, A.; Vullo, D.; Supuran, C. T.; Poulsen, S. A. Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linkedO-glycosidesofbenzenesulfonamides. J.Med.Chem. 2007,50,1651-1657.
164. Shank, R. P.; Gardocki, J. F.; Vaught, J. L.; Davis, C. B.; Schupsky, J. J.; Raffa, R. B.; Dodgson, S. J.; Nortey, S. O.; Maryanoff, B. E. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 1994, 35, 450-460.
165. Edmonds, H. L., Jr.; Jiang, Y. D.; Zhang, P. Y.; Shank, R. P. Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. Life Sci. 1996, 59, PL127-PL131.
166. Stringer, J. L. A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat. Epilepsy Res. 2000, 40, 147-153.
167. Sabers, A.; Gram, L. Newer anticonvulsants: comparative reviewof drug interactions and adverse effects. Drugs 2000, 60, 23-33.
168. Bourgeois, B. F. Pharmacokinetics and pharmacodynamics of topiramate. J. Child. Neurol. 2000, 15, S27-S30.
169. Bialer, M.; Johannessen, S. I.; Kupferberg, H. J.; Levy, R. H.; Loiseau, P.; Perucca, E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001, 43, 11-58.
170. Gordon, A.; Price, L. H. Mood stabilization and weight loss with topiramate. Am. J. Psychiatry 1999, 156, 968-969.
171. Maryanoff, B. E.; Costanzo, M. J.; Nortey, S. O.; Greco, M. N.; Shank, R. P.; Schupsky, J. J.; Ortegon, M. E.; Vaught, J. L. Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. J. Med. Chem. 1998, 41, 1315-1343.
172. Recacha, R.; Costanzo, M. J.; Maryanoff, B. E.; Chattopadhyay, D. Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulfamate. Biochem. J. 2002, 361, 437-441.